Kwangmeyung Kim

46PUBLICATIONS
30CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Dec 12, 2025
Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.

Joohee Jeong, Hanhee Cho, Yujeong Moon

|Dec 03, 2025
Cathepsin B-Cleavable Doxorubicin Prodrug Nanoparticles for Eliciting Cancer-Specific Immunogenic Cell Death and Minimizing Systemic Toxicity.

Nayeon Shim, Jinseong Kim, Sukyung Song

|Sep 26, 2025
Nanotechnology-based strategies for overcoming clinical limitations of PROTACs in cancer therapy.

Hanhee Cho, Jinseong Kim, Hoyeon Lee

|Jul 21, 2025
Cancer-Specific and Pro-Apoptotic PEGylated Liposomes Containing SMAC-Mimetic Doxorubicin Prodrug for Safe High-Dose Delivery in Pancreatic Cancer.

Yeonjin Kim, Jinseong Kim, Ji Hye Jeong

|Apr 29, 2025
Dual Delivery of Light/Prodrug Nanoparticles Using Tumor-Implantable Micro Light-Emitting Diode on an Optofluidic System for Combinational Glioma Treatment.

Jagyeong Goo, Jun Seo Lee, Junwon Park

|Jan 08, 2025
Nanotechnology-Based Strategies for Safe and Effective Immunotherapy.

Seeun Hong, Juwon Park, Yoojeong Oh

Pageof 8

Frequent Collaborators

11 joint publications

Hong Yeol Yoon

3 joint publications

Dong-Kwon Lim

3 joint publications

Byung-Soo Kim

3 joint publications

In-Cheol Sun